<DOC>
	<DOCNO>NCT02113020</DOCNO>
	<brief_summary>The objective clinical trial examine clinical pharmacology property TAK-233 healthy female subject</brief_summary>
	<brief_title>A Phase I Clinical Pharmacology Study TAK-233 Healthy Subjects</brief_title>
	<detailed_description>The primary objective study examine pharmacodynamics safety TAK-233 administer single dose healthy woman .</detailed_description>
	<criteria>1 . Subjects understand content clinical trial investigator subinvestigator consider able comply procedure clinical trial 2 . Subjects sign inform consent form date form without assistance starting procedure clinical trial 3 . Healthy Japanese woman 4 . Subjects age ≥ 20 ≤ 40 year time consent 5 . Subjects body weight ≥ 45 kg BMI ≥18.5 ≤ 25.0 kg/m2 time screen 6 . Women child bear potential agree take specify contraceptive measure regularly time consent 4 week end last assessment fourth treatment period 1 . Subjects receive TAK233 within 16 week start initial administration 2 . Subjects previously receive TAK233 treatment participation another clinical trial 3 . Employees medical institution conduct clinical trial family/dependents ( e.g. , husband wife , parent , child , sibling ) , subject may coerce agree participate clinical trial 4 . Subjects poorly control clinically significant neurological , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal ( include chronic costiveness ) , urological ( include dysuria ) , autoimmune , endocrine , psychiatric disease abnormality may affect subject 's participation clinical trial result clinical trial 5 . Subjects hypersensitivity TAK233 related substance , excipients product 6 . Subjects whose urine test positive drug abuse screen 7 . Subjects history drug abuse ( define use illegal drug ) alcohol dependence within 52 week screen assessment , subject willing stop alcohol intake drug use participation clinical trial 8 . Subjects need take prohibit concomitant medication , vitamin , food list list ? 9 . Pregnant lactate woman , woman expect pregnant give consent , clinical trial , within 4 week completion clinical trial , woman plan donate ova period 10 . Subjects currently active cardiovascular disease , central nervous system disease , hepatic disease , hematopoietic disease , renal failure , metabolic disorder , endocrine disorder , serious allergy , asthma , hypoxemia , hypertension , convulsion , allergic exanthema , urological disorder ( subject peptic ulcer , convulsive disorder , arrhythmia also fall category ) 11 . Subjects follow diseases/surgical intervention may affect drug absorption : digestive system disorder ( malabsorption , esophageal reflux , peptic ulcer , erosive oesophagitis , frequent heartburn ( least week ) , surgical intervention ( e.g. , cholecystectomy ) , subject prior history diseases/surgical intervention within last 24 week 12 . Subjects history cancer ( exclude subject whose basal cell carcinoma remission least 5 year 13 . Subjects test positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antigen/antibody , syphilis serological reaction screen 14 . Subjects take nicotinecontaining product ( e.g. , cigarette , pipe tobacco , cigar , chew tobacco , nicotine patch , nicotine gum ) within 28 day hospitalization 15 . Subjects blood collection peripheral vein difficult 16 . Subjects donate least 200 mL whole blood within 4 week start initial administration , subject donate least 400 mL whole blood within 16 week start initial administration 17 . Subjects donate least 400 mL ( total ) whole blood within 52 week start initial administration 18 . Subjects donate blood component within 2 week start initial administration 19 . Subjects clinically significant abnormality electrocardiogram record screening hospitalization ( Day 1 first treatment period ) 20 . Subjects QTcF interval &gt; 470 msec PR interval &lt; 120 msec &gt; 220 msec electrocardiogram record screen hospitalization 21 . Subjects systolic blood pressure &lt; 100 mmHg &gt; 140 mmHg diastolic blood pressure &lt; 60 mmHg &gt; 90 mmHg screen hospitalization 22 . Subjects heart rate &lt; 50 bpm &gt; 90 bpm screen hospitalization 22 . Subjects unlikely comply protocol , subject investigator subinvestigator considers ineligible participation clinical trial due reason</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>